about
A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discoveredThe role of maintenance therapy in acute promyelocytic leukemia in the first complete remissionGATA-3 links tumor differentiation and dissemination in a luminal breast cancer modelInhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cellsInhibition of histone deacetylases in cancer therapy: lessons from leukaemiaAcute promyelocytic leukemia: where did we start, where are we now, and the futureNew IDH1 mutant inhibitors for treatment of acute myeloid leukemiaAll trans retinoic acid in acute promyelocytic leukemia.Regulation of Cellular Identity in CancerAcute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patientsIdentification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mappingATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistanceExpert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extractsPharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes.Therapy of acute myeloid leukemia.Literature Lab: a method of automated literature interrogation to infer biology from microarray analysis.Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature.Gut Microbiota Species Can Provoke both Inflammatory and Tolerogenic Immune Responses in Human Dendritic Cells Mediated by Retinoic Acid Receptor Alpha Ligation.Minireview: Nuclear receptors, hematopoiesis, and stem cells.Extramedullary disease in acute promyelocytic leukemia.All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia.Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. The Medical Research Council (MRC) Adult Leukaemia Working Party.Curing all patients with acute promyelocytic leukemia: are we there yet?Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.Retinoids: present role and future potential.Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemiaDetection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance.The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease.The quest to overcome resistance to EGFR-targeted therapies in cancer.In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications.Management of relapsed acute myeloid leukaemia.Synergy of Transforming Growth Factor Beta 1 and All Trans Retinoic Acid in the Treatment of Inflammatory Bowel Disease: Role of Regulatory T cells.Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapyRetinoid signaling regulates breast cancer stem cell differentiation.Cytogenetics and molecular genetics of childhood leukemia.Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.STAT signaling in the pathogenesis and treatment of leukemias.Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy.
P2860
Q23671266-2BDDA722-99A3-4A1F-9F79-EE4DC653CDB3Q24200224-E5B00003-3138-4B1F-B21C-562201161549Q24657350-2581FC7B-3BCB-43DC-B1A3-31272DDD7655Q24676524-1FFD9F16-40BB-4178-8422-64DD1F9803CEQ26767024-0C785F77-F4B9-4F68-90CE-3F810E384F88Q26830385-9E9985F4-FE07-4F84-B445-D5324C83A27EQ27702240-DF36125E-8A9A-445E-A389-2D7E7618B874Q27824776-18E90905-0D2B-4B4F-A7FA-1FB1FEDD96BCQ28086849-4A736CF9-75FB-4DF0-A9FC-5B544E117B90Q28286577-9B4C0A29-3E8A-4628-8A8D-B3397A776193Q28477029-C8DE7355-5474-416A-9180-C66FEEDEB62BQ28540033-CA2E9B9C-7915-4970-A078-DF1166184276Q30401812-FEF1A334-917D-40BC-8738-8BA875C97C6EQ30676818-16EB9967-11C7-431F-9C11-2041FCD1625FQ30977623-8DA6144E-111D-47EA-94AE-ED8F67535458Q31929964-0C83F2E1-6688-4472-A167-417F5AAB906FQ33310992-5E9F482E-4235-4801-A013-26844C92216DQ33365781-98C7B581-C228-448B-9DA4-76135368F18DQ33571508-7233D0CB-11E0-4F79-BABA-BC06FE14B669Q33576478-7C6C84DE-6235-4153-816E-9D0FFD2E12BEQ33604339-2588269E-D459-451A-B8A3-70AD3D95A12EQ33604359-1A989BDD-E440-48EC-B7F5-19089B80574DQ33610823-F2E137AF-0F11-44BC-8D90-DCE4EF8FACFDQ33613426-C6E95EDA-2FF5-4BCC-9504-660C4BC4DC2FQ33631350-23F7CC14-8955-43E8-B980-36B38023C57FQ33676667-D54B6CE2-BFFC-46B8-B038-E5F11248FB08Q33710730-DD9DD50A-9F6D-4C46-870E-153929C6AF22Q33723603-952BAF44-AC47-4A02-BB95-4D46A1071AD5Q33723609-486106B4-24D6-44E6-90FF-0EFF77711CF3Q33725976-321A124C-45F8-4482-A0D1-60CB88A18EF8Q33739259-F7529025-ACA5-49FC-B35A-AA87EEF75E7CQ33751243-F1BEFAF5-8B8D-4EC7-9EC4-A5076CE3558FQ33772861-A4AAF575-72FE-4480-9DA7-5925167DC71CQ33781722-20ADB4CF-B7DA-45F0-9EC3-27D728D4AB6FQ33817989-CB83F7DB-4585-428A-888E-75F3D01C11EAQ33820790-12BDF496-F901-44C2-A2AC-4D3B93966E58Q33929824-90030D92-D61F-4A13-A3F7-504FCDD8B255Q33941357-9F03FD9E-A4A4-4FF9-86BE-B5E3930AA27EQ34035750-56A5B3CB-79DC-4C5C-800E-0BCD6CC1118BQ34064907-4A52C187-2952-464B-88EE-2EE04B59C1CD
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
All-trans-retinoic acid in acute promyelocytic leukemia
@ast
All-trans-retinoic acid in acute promyelocytic leukemia
@en
All-trans-retinoic acid in acute promyelocytic leukemia
@nl
type
label
All-trans-retinoic acid in acute promyelocytic leukemia
@ast
All-trans-retinoic acid in acute promyelocytic leukemia
@en
All-trans-retinoic acid in acute promyelocytic leukemia
@nl
prefLabel
All-trans-retinoic acid in acute promyelocytic leukemia
@ast
All-trans-retinoic acid in acute promyelocytic leukemia
@en
All-trans-retinoic acid in acute promyelocytic leukemia
@nl
P2093
P3181
P1476
All-trans-retinoic acid in acute promyelocytic leukemia
@en
P2093
C A Schiffer
J H Feusner
J W Andersen
L Shepherd
M S Tallman
P H Wiernik
P304
P3181
P356
10.1056/NEJM199710093371501
P407
P577
1997-10-09T00:00:00Z